Proximal GATA-binding sites are essential for human \textit{HSD3B1} gene transcription in the placenta

Tsai-Chun Lai\textsuperscript{1}, Hsiao-Fang Li\textsuperscript{1}, Yu-Shian Li\textsuperscript{1}, Pei-Yu Hung\textsuperscript{1}, Ming-Kwang Shyu\textsuperscript{2} & Meng-Chun Hu\textsuperscript{1,3}

The enzyme 3β-hydroxysteroid dehydrogenase/isomerase (3β-HSD) is involved in the synthesis of active steroid hormones. Two human 3β-HSD isoforms are expressed in a tissue-specific pattern. \textit{HSD3B1} (type I) expression is essential to produce progesterone for pregnancy maintenance. To understand the mechanisms of human \textit{HSD3B1} activation in the placenta, 2.2 kb of 5′-flanking sequence and 5′-deletions were fused to the luciferase reporter gene and transfected into human JEG-3 cells. The proximal −238/+337 sequence had the highest promoter activity. Two GATA elements were identified at −106/−99 and −52/−45. Mutations of either sites greatly reduced promoter activity in JEG-3 cells, demonstrating the importance of GATA sites. EMSA revealed the specific binding of GATA2 and GATA3 to the GATA sequences at −328/−353 and −389/−409. ChIP assays demonstrated the association of GATA2 but not GATA3 with the GATA-binding regions of the \textit{HSD3B1} promoter in JEG-3 cells. GATA2 knockdown significantly reduced \textit{HSD3B1} expression in JEG-3 cells; however, GATA3 knockdown increased \textit{HSD3B1} expression. Western blot analysis revealed high levels of GATA2 but not GATA3 in human placental tissues. This study identified GATA motifs as essential control elements for \textit{HSD3B1} transcription and GATA2 as a novel transcriptional regulator of \textit{HSD3B1} expression in the human placenta.

The enzyme 3β-hydroxysteroid dehydrogenase/isomerase (3β-HSD) regulates an essential step in the biosynthesis of steroid hormones, including mineralocorticoids, glucocorticoids, and sex steroids\textsuperscript{1}. Multiple isoforms of 3β-HSD have been identified in humans and rodents. These isoforms are encoded by distinct genes and are expressed in a tissue-specific pattern\textsuperscript{2}. Humans possess two 3β-HSD isoforms, type I (\textit{HSD3B1}) and type II (\textit{HSD3B2}), which share 93.5% identity in their amino acid sequences\textsuperscript{3}. \textit{HSD3B2} is exclusively expressed in the classic steroidogenic tissues including the adrenal gland, ovary, and testis, whereas \textit{HSD3B1} is expressed in the placenta and peripheral tissues, including the mammary gland, prostate, and skin\textsuperscript{3–5}.

Progesterone is essential for the establishment and maintenance of pregnancy in mammals. The biosynthesis of progesterone from cholesterol is catalysed by two steroidogenic enzymes: cytochrome P450 side-chain cleavage enzyme (P450scc; encoded by \textit{CYP11A1}) and 3β-HSD. During the early stages of human pregnancy, the corpus luteum of the ovary is active in secreting progesterone for the implantation and maintenance of pregnancy\textsuperscript{6}. After about 8–10 weeks, large amounts of progesterone are produced by the placenta to sustain the pregnancy. The expression of \textit{HSD3B1} in the placenta is involved in the biosynthesis of progesterone; thus, it is needed for successful pregnancy. Little is known about the molecular mechanisms that regulate \textit{HSD3B1} expression in the placenta. Previous studies have demonstrated that stimulation with cAMP and PMA (phorbol 12-myristate 13-acetate) can increase \textit{HSD3B1} mRNA in human choriocarcinoma JEG-3 cells\textsuperscript{7}; however, no response elements have been identified in the promoter of the \textit{HSD3B1} gene. An initial study investigating the regulatory sequences of the \textit{HSD3B1} promoter has demonstrated that some cis-acting elements located in the first intron regulate the basal expression of the \textit{HSD3B1} gene\textsuperscript{8}. Furthermore, a distal cis-regulatory element located at −2570/−2518 mediates the specific expression of the \textit{HSD3B1} gene in the placenta\textsuperscript{8}. This element contains a specific binding site for transcription enhancer factor (TEF)-5, which is highly expressed in the human placenta, and an overlapping GATA-binding site for a GATA-like protein.

\textsuperscript{1}Graduate Institute of Physiology, National Taiwan University College of Medicine, Taipei, 100, Taiwan. \textsuperscript{2}Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, 100, Taiwan. Correspondence and requests for materials should be addressed to M.-C.H. (email: mengchun@ntu.edu.tw)
In this study, we searched for novel regulatory elements within the 2.2 kb proximal promoter of HSD3B1. We identified two GATA elements located at –106/−99 and –52/−45 that are essential for the functional activity of the HSD3B1 promoter in JEG-3 cells. Our data revealed that GATA2 and GATA3 are predominant proteins bound to the GATA elements and may play distinct functional roles in the expression of HSD3B1 in the placenta.

**Results**

**Promoter activity of human HSD3B1 gene in JEG-3 cells.** To identify novel regulatory elements involved in the placentual expression of human HSD3B1 gene, the 5′-flanking sequence from –2226 to +337 was cloned upstream of the luciferase reporter gene. In addition, the luciferase reporter construct containing the promoter fragment (−1859/+556) from human HSD3B2 gene was also generated. In human JEG-3 trophoblast cells, the HSD3B1 −2226/+337 fragment demonstrated a marked increase in transcriptional activity (35 fold) over the basic vector, whereas the −1859/+556 fragment of the HSD3B2 promoter did not exhibit luciferase activity (Fig. 1A), indicating the specific expression of HSD3B1 in the placenta. This finding suggests that sequences between −2226 to +337 contain functional elements for the regulation of HSD3B1 expression in JEG-3 cells. To further localise the regulatory cis-elements in this region, the −2226/+337 fragment was used to generate a series of deletions. As shown in Fig. 1B, the −238/+337 construct had the highest promoter activity in JEG-3 cells. Furthermore, the deletion of 262 bp from −500 to −238 resulted in a drastic increase in transcriptional activity by 4.5 fold, suggesting the presence of negative regulatory elements in this region. These data demonstrate that the −238/+337 basal promoter region contains functional cis-elements responsible for HSD3B1 expression in the placenta.

**Enhancement of HSD3B1 promoter activity by GATA2 and GATA3.** A database search of the −238/+337 promoter region identified two putative GATA-binding sites at –106/−99 and –52/−45, which are referred to as Gu and Gp, respectively. To determine the role of these GATA-binding sites in the regulation of HSD3B1 promoter activity, mutated GATA-binding sequences were introduced into the −238/+337 promoter construct (Fig. 2A). As shown in Fig. 2B, mutations of Gu and Gp significantly reduced promoter activity by 87% and 58%, respectively, in JEG-3 cells. In addition, the simultaneous mutation of both GATA sites resulted in a 93% reduction in promoter activity that was significantly lower than the Gu mutation (**P** < 0.05). These results suggested that both the Gu and Gp sites are involved in the regulation of HSD3B1 promoter activity.

The GATA transcription factor family consists of six members, GATA1–GATA6. GATA2 and GATA3 have previously been reported to regulate the expression of a number of genes in trophoblast cells and placental tissues. To determine whether GATA proteins affect HSD3B1 promoter activity, the −238/Luc construct was co-transfected with GATA expression plasmids in HeLa cells. As shown in Fig. 3A, co-transfection of the −238/Luc construct with GATA2 or GATA3 significantly increased promoter activity, whereas co-transfection with GATA4 did not affect reporter activity. Mutation of the Gu or Gp GATA-binding site resulted in the loss of GATA2- and GATA3-stimulated promoter activity (Fig. 3C and D).

**Expression of 3β-HSD, GATA 2, and GATA3 in the placenta.** As shown in Fig. 4A, we confirmed the expression of 3β-HSD protein in JEG-3 cells by western blot analysis. The 3β-HSD type 2 is the isoform expressed...
in human adrenals; thus, a high amount of 3β-HSD protein was detected in H295R human adrenocortical carcinoma cells (Fig. 4A). In addition, Fig. 4A shows that GATA2 and GATA3 proteins were present at high levels in JEG-3 cells but at low to undetectable levels in H295R, HepG2, HeLa, or HEK293T cells. This is consistent with earlier studies showing the high expression of GATA2 and GATA3 in JEG-3 cells but not in H295R cellsⁿ, ¹². Cellular fractionation experiments demonstrated that GATA2 and GATA3 proteins were exclusively present in the nuclear fraction of JEG-3 cells (Fig. 4B).

The expressions of 3β-HSD, GATA 2, and GATA3 were examined in placental tissues by western blot analysis. Mouse 3β-HSD 6 is orthologous to human 3β-HSD 1, which is the only isoform expressed in the placenta and skin¹³. Consistent with previous studies, we found that 3β-HSD protein was highly expressed in mouse placenta on E10.5 and gradually decreased from E11.5–E12.5 (Fig. 4C). Similar to 3β-HSD, protein levels of GATA2 and GATA3 were high in mouse placenta on E10.5 and declined thereafter. However, GATA3 protein level was markedly decreased on E11.5. The protein expressions of 3β-HSD and GATA2 were also high in human placental tissues; conversely, GATA3 protein was detected at a very low level (Fig. 4C).

**Analysis of GATA2 and GATA3 binding to the GATA elements.** We performed electrophoretic mobility shift assay (EMSA) to examine the potential nuclear proteins involved in binding to the GATA-binding sites. Synthetic oligonucleotides containing the GATA site Gu (−115/−86) and Gp (−65/−36) were used as probes. Nuclear extracts from JEG-3 cells formed DNA-protein complexes with Gu probe (Fig. 5A, lane 2) that were competed by a 100-fold excess of unlabelled Gu (lane 3) or Gp (lane 4) probe. Similarly, protein complexes formed from JEG-3 nuclear extracts and Gp probe were competed by an excess of unlabelled Gu (lane 10) or Gp (lane 11) probe. Probes with mutation of the GATA-binding sequences (mu and mp) shown in Fig. 2 did not compete with the complexes (lane 5, 6, 12, and 13), indicating that the GATA sequence is required for protein binding. With Gu or Gp as the probe, a supershift was observed by the antiserum to GATA2 or GATA3, but not by the control serum (Fig. 5B). This suggests the involvement of GATA2 and GATA3 in the DNA-protein complex observed in EMSA. Furthermore, we used ChIP assays to confirm the presence of GATA2 or GATA3 at the endogenous promoter in JEG-3. As shown in Fig. 5C, GATA2 occupancy was observed in the GATA-binding region of the HDS3B1 promoter, whereas GATA3 was not found to be associated with this region.

**Effects of GATA2 or GATA3 knockdown on HSD3B1 expression.** To determine the roles of GATA2 and GATA3 in regulating HSD3B1 expression, we used shRNA to knock down GATA2 or GATA3 in JEG-3 cells. As shown in Fig. 6A and B, knockdown of GATA2 markedly reduced HSD3B1 mRNA levels by ~80% and protein levels by ~70% in JEG-3 cells. In contrast, we observed that GATA3 knockdown resulted in a 2-fold increase in
the mRNA and protein levels of HSD3B1 (Fig. 6C and D). The results suggest that GATA2 and GATA3 may play distinct functional roles in HSD3B1 transcription.

Discussion

Human HSD3B1 is involved in the production of placental progesterone for maintenance of pregnancy. Although several cis-acting elements have been implicated in the transcription of HSD3B1, the transcriptional mechanisms that regulate its basal expression in the placenta remain unknown. Here, we found that the proximal −238/+337 sequence of HSD3B1 exhibited high promoter activity in human choriocarcinoma JEG-3 cells. In this region, two GATA elements were identified at −287/−310 (Gu) and −310/−382 (Gp). Mutation of the GATA-binding sites at Gu or Gp greatly reduced promoter activity in JEG-3 cells. Our findings in this study strongly suggest that the proximal GATA motifs are important for trophoblast-specific expression of the HSD3B1 gene, and GATA2 and GATA3 play a role in the regulation of HSD3B1.

GATA transcription factors have conserved zinc finger domains that bind to the consensus DNA motif [(A/T)GATA(A/G)] to regulate the transcription of downstream genes. In mammals, six GATA factors are expressed in a tissue-specific manner and involved in the regulation of cell-specific gene expression. Earlier studies have indicated that GATA2 and GATA3 are the isoforms predominantly expressed in placental trophoblast cells, regulating the expression of a number of genes such as placental lactogen I, prolifier, and syncytin.10, 14, 15. Our study showed that both GATA2 and GATA3 proteins were abundantly expressed in JEG-3 trophoblast cells and placental tissues (Fig. 4). GATA2 and GATA3 exhibited similar temporal expression patterns to HSD3B1 in mouse
placenta. Furthermore, overexpression of GATA2 or GATA3 significantly stimulated HSD3B1 promoter activity in non-trophoblast cells (HeLa cells), whereas GATA4 had no effect on HSD3B1 promoter activity (Fig. 3). Mutations of GATA-binding sites significantly impaired GATA2- or GATA3-induced HSD3B1 promoter activity. In addition, EMSA experiments demonstrated the specific binding of GATA2 and GATA3 proteins to the GATA sequences at −106/−99 and −264/−282. These data suggest that GATA2 and GATA3 can regulate the transcription of HSD3B1 through the GATA-binding sequences.

In EMSA, we observed that the two GATA probes (Gu and Gp) seemed to bind with a stronger affinity to GATA2 than to GATA3 (Fig. 5B). ChIP-qPCR assays further verified the binding of GATA2 at the GATA-binding regions of the HSD3B1 promoter in JEG-3 cells. GATA2 knockdown in JEG-3 cells resulted in a sharp reduction in the expression of HSD3B1. Together, these findings reveal that GATA2 is the predominant protein recruited to the GATA motifs at −106/−45 to stimulate HSD3B1 gene expression in JEG-3 cells. In addition to the placenta, the expression of HSD3B1 has been identified in peripheral tissues including the mammary gland, prostate, and several human cancer cell lines3–5. The LNCaP human prostate cancer cells have been shown to express low levels of endogenous HSD3B1.16. GATA2 ChIP-seq data derived from LNCaP cells are available in the GEO (Gene Expression Omnibus) database under accession number GSE69043.17 Analysis of the ChIP-seq datasets for LNCaP cells revealed GATA2 ChIP enrichment in the regulatory regions of the HSD3B1 locus between −267 and +104 (Supplementary Fig. S1), covering the two GATA-binding sites identified in this study. This is consistent with our ChIP-qPCR results of GATA2 in JEG-3, strongly indicating that GATA2 may be necessary for the basal transcription of the HSD3B1 gene.

In contrast to GATA2, the levels of HSD3B1 mRNA and protein were increased by GATA3 knockdown in JEG-3 cells, indicating that GATA3 may negatively regulate the expression of HSD3B1. EMSA experiments showed that both GATA2 and GATA3 were able to bind to the GATA elements at −106/−45 in vitro (Fig. 5B), suggesting that GATA2 and GATA3 may occupy identical GATA-binding regions of the HSD3B1 locus but exert distinct activities in HSD3B1 expression. Similar findings demonstrating that GATA factors exhibit different functions through shared chromatin sites were also observed in the transcriptional regulation of the Gata2
gene. During mouse erythroid differentiation, GATA1 and GATA2 directly regulate Gata2 transcription. GATA1 represses Gata2 transcription by displacement of GATA2 from certain GATA-binding sites in the upstream region.

**Figure 5.** Analysis of GATA2 and GATA3 binding to sites at −106/−45 in the HSD3B1 promoter. EMSA was performed with JEG-3 nuclear extract (NE) using two radiolabelled probes containing the putative GATA-binding site Gu (−115/−86) or Gp (−65/−36). (A) Competition experiments were performed by incubation with a 100-fold excess of the unlabelled oligonucleotides Gu, Gp, mutated Gu (mu), mutated Gp (mp), or non-specific sequence (NS). (B) The anti-GATA2 or anti-GATA3 antibody was added to the binding reaction, and the respective isotype antibody was used as a control. Supershift bands are indicated by the arrowhead. (C) JEG-3 cells were subjected to ChIP assay with the indicated antibodies or control IgG and analysed by qPCR using a primer set (indicated by arrows) covering the Gp site. The PCR-amplified fragment is 107 bp (−96~+11). Representative results of two independent experiments are shown. Data are means ± SD of triplicate qPCR analyses. Uncropped images of blots were shown in Supplementary Fig. S5.
GATA2 is transcriptionally active in these regions, indicating that it positively autoregulates transcription. The process of “GATA switch” was also found in the development of the placenta. GATA3 was reported to repress the 

**HSD3B1**

gene by occupying the −3.9 kb and +9.5 kb regions of the 

**HSD3B1**

locus in undifferentiated trophoblast cells. The displacement of GATA3 by GATA2 at these regions induces 

**HSD3B1**

transcription during trophoblast differentiation. If a similar GATA switch occurs in the 

**HSD3B1**

locus, the concentration of GATA2 and GATA3 may be an important determinant in 

**HSD3B1**

gene regulation. In the present study, we showed that GATA3 protein was scarce in human placental tissues (Fig. 4C). In contrast, GATA2 protein was present at high levels, suggesting the binding of GATA2 to the GATA sites in the promoter to induce 

**HSD3B1**

transcription.

Although both GATA3 and GATA2 were abundant in JEG-3 cells, GATA3 binding to the GATA sites at −106/-45 was not observed in ChIP assays, indicating that this region may not be involved in GATA3-mediated 

**HSD3B1**

repression. Piao et al. identified a GATA3-binding motif in a silencer element that represses the transcriptional activity of the 

**HSD17B1**

promoter in choriocarcinoma cells. By using a transcription factor binding site search program, we identified another putative GATA element present between −558 and −547 of the 

**HSD3B1**

promoter (Supplementary Fig. S2). Mutation of the GATA sequence in this region increased the promoter activity in JEG-3 cells, indicating that this motif is a potential silencer of the 

**HSD3B1**

gene. However, the specific association of GATA proteins to this GATA element was not detectable by EMSA analysis. Whether other GATA3-binding sites are present in the 

**HSD3B1**

locus and participate in the regulation of 

**HSD3B1**

transcription remain to be determined.

The expressions of 

**CYP11A1**

and 

**HSD3B1**

are required for the synthesis of progesterone in the human placenta. A previous study identified a GATA element at −475/-470 that is required for the activation of the 

**Cyp11a1**

promoter in mouse trophoblast giant cells. The study demonstrated via EMSA that GATA2 is the predominant protein bound to this GATA site. In this study, we found that two GATA-binding motifs located at −106/-45 are essential for the activation of the 

**HSD3B1**

promoter in human trophoblast cells. Our data demonstrate that GATA2 binds to the GATA motifs and acts as the critical transcriptional activator of the 

**HSD3B1**

gene in trophoblast cells. In addition, GATA3 seems to exert suppressive effects on 

**HSD3B1**

gene transcription. Together, GATA2 and GATA3 may play a critical role in the regulation of placental progesterone production.

**Methods**

**Plasmids.** The 5′-flanking regions of human 

**HSD3B1**

(−2,226/+337) and 

**HSD3B2**

(−1,859/+556) were cloned into the pGL3-Basic luciferase vector to generate pHSD3B1-2.2k-Luc and pHSD3B2-1.8k-Luc, respectively. pHSD3B1-1k-Luc was constructed by inserting the MluI-SwaI fragment (−1069/+337) into pGL3-Basic. pHSD3B1-0.5k-Luc was constructed by cloning the PCR-amplified −500/+337 fragment from pHSD3B1-2.2k-Luc into pGL3-Basic. pHSD3B1-0.2k-Luc was constructed by inserting the MluI-PvuII fragment (−238/+337)
into pGL3-Basic. Mutations of the GATA-binding sites of pHSD3B1-0.2k-Luc or pHSD3B1-1k-Luc were generated by PCR-based site-directed mutagenesis. Human cDNAs of GATA2 and GATA4 were PCR-amplified and ligated to expression vector to generate Myc-tagged GATA2 and Myc-tagged GATA4, respectively. The expression plasmid pcDNA3-GATA3 for human GATA3 was a generous gift from S.-C. Miaw (Graduate Institute of Immunology, National Taiwan University College of Medicine).

Human tissues and animals. Human placental tissues were collected at term from the Department of Obstetrics and Gynecology, National Taiwan University Hospital (NTUH). The study protocol was approved by the institutional review board (IRB: 20140605RINC) at NTUH. The informed consent was obtained from all subjects. Animal experiments were approved by the National Taiwan University College of Medicine and College of Public Health Institutional Animal Care and Use Committee. All methods were performed in accordance with the relevant guidelines and regulations. C57BL/6J mice were mated and checked for vaginal plugs the next morning. Noon on the day the vaginal plug was observed was considered embryonic day 0.5 (E0.5). Pregnant female mice were killed by CO2 at the indicated times in the figure. Uterine horns were removed, and the placenta was separated from the embryo.

Cell culture and transfection. JEG-3 cells were maintained in DMEM/F12 supplemented with 10% foetal bovine serum. Authenticity of JEG-3 cell line was confirmed using short tandem repeat (STR) profiling by Promega (Madison, WI, USA). The test was performed by using the PromegaGenePrint® 10 System and analysed by ABI PRISM 3730 GENETIC ANALYZER and GeneMapper® Software V3.7. HeLa cells were grown in DMEM containing 10% foetal bovine serum. Cell transfections were performed by GenJet™ In Vitro DNA Transfection Reagent (Ver. II) (SignaGen).

Luciferase assay. Cells were subcultured 24 h before transfection in 24-well plates at a density of 10⁵ cells/well. Cells were transfected with 100 ng of reporter plasmid and 10 ng of the control reporter phRLuc. After 24 h, cells were harvested, and luciferase activity was determined using the Dual-Glo Luciferase Assay System (Promega). The results were normalised to internal Renilla luciferase activity. Data were obtained from at least three independent experiments. The significance of differences between group means was determined using one-way ANOVA followed by Newman-Keuls post-test. The statistical analysis were performed with GraphPad Prism 6 software (GraphPad Software).

Cellular extraction, subcellular fractionation, and western blot analysis. Total cell lysates were prepared by lysing cells in modified RIPA buffer [25 mM Tris/HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, 5 mM EDTA, 1 mM EGTA, 5 mM DTT, 2 mM PMSF, and 10 μg/ml leupeptin]. Cytoplasmic and nuclear fractions were performed. Initially, cells were lysed in buffer A (10 mM HEPES pH 7.9, 10 mM KCl, 1.5 mM MgCl₂, 0.5% NP-40, 5 mM EDTA, 2 mM PMSF, and 10 μg/ml leupeptin) on ice for 30 min. After centrifugation (13,000 g for 10 min at 4°C), the supernatant was collected as the cytoplasmic fraction, and the nuclear pellet was washed with buffer A and centrifuged. The pellet was then resuspended in buffer B (20 mM HEPES pH 7.9, 0.42 M NaCl, 0.2 mM EDTA, 1.5 mM MgCl₂, 25% glycerol, 5 mM DTT, 2 mM PMSF, and 10 μg/ml leupeptin). After sonication and centrifugation (13,000 g for 10 min at 4°C), the supernatant was retained as the nuclear fraction. Proteins were separated by SDS-PAGE and subjected to western blot analysis. Antibodies against GATA3 and HSD3B were purchased from Santa Cruz Biotechnology, and GATA2 antibody was retained as the nuclear fraction. Proteins were separated by SDS-PAGE and subjected to western blot analysis. Antibodies against GATA3 and HSD3B were purchased from Santa Cruz Biotechnology, and GATA2 antibody was retained as the nuclear fraction. Proteins were separated by SDS-PAGE and subjected to western blot analysis. Antibodies against GATA3 and HSD3B were purchased from Santa Cruz Biotechnology, and GATA2 antibody was retained as the nuclear fraction. Proteins were separated by SDS-PAGE and subjected to western blot analysis. Antibodies against GATA3 and HSD3B were purchased from Santa Cruz Biotechnology, and GATA2 antibody was retained as the nuclear fraction. Proteins were separated by SDS-PAGE and subjected to western blot analysis. Antibodies against GATA3 and HSD3B were purchased from Santa Cruz Biotechnology, and GATA2 antibody was retained as the nuclear fraction. Proteins were separated by SDS-PAGE and subjected to western blot analysis. Antibodies against GATA3 and HSD3B were purchased from Santa Cruz Biotechnology, and GATA2 antibody was retained as the nuclear fraction. Proteins were separated by SDS-PAGE and subjected to western blot analysis. Antibodies against GATA3 and HSD3B were purchased from Santa Cruz Biotechnology, and GATA2 antibody was retained as the nuclear fraction. Proteins were separated by SDS-PAGE and subjected to western blot analysis. Antibodies against GATA3 and HSD3B were purchased from Santa Cruz Biotechnology, and GATA2 antibody was retained as the nuclear fraction. Proteins were separated by SDS-PAGE and subjected to western blot analysis. Antibodies against GATA3 and HSD3B were purchased from Santa Cruz Biotechnology, and GATA2 antibody was retained as the nuclear fraction. Proteins were separated by SDS-PAGE and subjected to western blot analysis. Antibodies against GATA3 and HSD3B were purchased from Santa Cruz Biotechnology, and GATA2 antibody was retained as the nuclear fraction. Proteins were separated by SDS-PAGE and subjected to western blot analysis. Antibodies against GATA3 and HSD3B were purchased from Santa Cruz Biotechnology, and GATA2 antibody was retained as the nuclear fraction. Proteins were separated by SDS-PAGE and subjected to western blot analysis. Antibodies against GATA3 and HSD3B were purchased from Santa Cruz Biotechnology, and GATA2 antibody was retained as the nuclear fraction. Proteins were separated by SDS-PAGE and subjected to western blot analysis. Antibodies against GATA3 and HSD3B were purchased from Santa Cruz Biotechnology, and GATA2 antibody was retained as the nuclear fraction. Proteins were separated by SDS-PAGE and subjected to western blot analysis. Antibodies against GATA3 and HSD3B were purchased from Santa Cruz Biotechnology, and GATA2 antibody was retained as the nuclear fraction. Proteins were separated by SDS-PAGE and subjected to western blot analysis. Antibodies against GATA3 and HSD3B were purchased from Santa Cruz Biotechnology, and GATA2 antibody was retained as the nuclear fraction. Proteins were separated by SDS-PAGE and subjected to western blot analysis. Antibodies against GATA3 and HSD3B were purchased from Santa Cruz Biotechnology, and GATA2 antibody was retained as the nuclear fraction. Proteins were separated by SDS-PAGE and subjected to western blot analysis. Antibodies against GATA3 and HSD3B were purchased from Santa Cruz Biotechnology, and GATA2 antibody was retained as the nuclear fraction. Proteins were separated by SDS-PAGE and subjected to western blot analysis. Antibodies against GATA3 and HSD3B were purchased from Santa Cruz Biotechnology, and GATA2 antibody was retained as the nuclear fraction. Proteins were separated by SDS-PAGE and subjected to western blot analysis. Antibodies against GATA3 and HSD3B were purchased from Santa Cruz Biotechnology, and GATA2 antibody was retained as the nuclear fraction. Proteins were separated by SDS-PAGE and subjected to western blot analysis. Antibodies against GATA3 and HSD3B were purchased from Santa Cruz Biotechnology, and GATA2 antibody was retained as the nuclear fraction. Proteins were separated by SDS-PAGE and subjected to western blot analysis. Antibodies against GATA3 and HSD3B were purchased from Santa Cruz Biotechnology, and GATA2 antibody was retained as the nuclear fraction. Proteins were separated by SDS-PAGE and subjected to western blot analysis. Antibodies against GATA3 and HSD3B were purchased from Santa Cruz Biotechnology, and GATA2 antibody was retained as the nuclear fraction. Proteins were separated by SDS-PAGE and subjected to western blot analysis. Antibodies against GATA3 and HSD3B were purchased from Santa Cruz Biotechnology, and GATA2 antibody was retained as the nuclear fraction. Proteins were separated by SDS-PAGE and subjected to western blot analysis. Antibodies against GATA3 and HSD3B were purchased from Santa Cruz Biotechnology, and GATA2 antibody was retained as the nuclear fraction. Proteins were separated by SDS-PAGE and subjected to western blot analysis. Antibodies against GATA3 and HSD3B were purchased from Santa Cruz Biotechnology, and GATA2 antibody was retained as the nuclear fraction. Proteins were separated by SDS-PAGE and subjected to western blot analysis. Antibodies against GATA3 and HSD3B were purchased from Santa Cruz Biotechnology, and GATA2 antibody was retained as the nuclear fraction. Proteins were separated by SDS-PAGE and subjected to western blot analysis. Antibodies against GATA3 and HSD3B were purchased from Santa Cruz Biotechnology, and GATA2 antibody was retained as the nuclear fraction. Proteins were separated by SDS-PAGE and subjected to western blot analysis. Antibodies against GATA3 and HSD3B were purchased from Santa Cruz Biotechnology, and GATA2 antibody was retained as the nuclear fraction. Proteins were separated by SDS-PAGE and subjected to western blot analysis. Antibodies against GATA3 and HSD3B were purchased from Santa Cruz Biotechnology, and GATA2 antibody was retained as the nuclear fraction. Proteins were separated by SDS-PAGE and subjected to western blot analysis. Antibodies against GATA3 and HSD3B were purchased from Santa Cruz Biotechnology, and GATA2 antibody was retained as the nuclear fraction. Proteins were separated by SDS-PAGE and subjected to western blot analysis. Antibodies against GATA3 and HSD3B were purchased from Santa Cruz Biotechnology, and GATA2 antibody was retained as the nuclear fraction. Proteins were separated by SDS-PAGE and subjected to western blot analysis. Antibodies against GATA3 and HSD3B were purchased from Santa Cruz Biotechnology, and GATA2 antibody was retained as the nuclear fraction. Proteins were separated by SDS-PAGE and subjected to western blot analysis. Antibodies against GATA3 and HSD3B were purchased from Santa Cruz Biotechnology, and GATA2 antibody was retained as the nuclear fraction. Proteins were separated by SDS-PAGE and subjected to western blot analysis. Antibodies against GATA3 and HSD3B were purchased from Santa Cruz Biotechnology, and GATA2 antibody was retained as the nuclear fraction. Proteins were separated by SDS-PAGE and subjected to western blot analysis. Antibodies against GATA3 and HSD3B were purchased from Santa Cruz Biotechnology, and GATA2 antibody was retained as the nuclear fraction. Proteins were separated by SDS-PAGE and subjected to western blot analysis. Antibodies against GATA3 and HSD3B were purchased from Santa Cruz Biotechnology, and GATA2 antibody was retained as the nuclear fraction. Proteins were separated by SDS-PAGE and subjected to western blot analysis. Antibodies against GATA3 and HSD3B were purchased from Santa Cruz Biotechnology, and GATA2 antibody was retained as the nuclear fraction. Proteins were separated by SDS-PAGE and subjected to western blot analysis. Antibodies against GATA3 and HSD3B were purchased from Santa Cruz Biotechnology, and GATA2 antibody was retained as the nuclear fraction.
by the 2-ΔΔCt method and normalised to β-actin in accordance with the manufacturer’s instructions (Thermo Fisher Scientific). Triplicate qPCR amplifications were performed for each sample. Data were obtained from three independent experiments. The significance of differences between means of two groups was determined using Student’s t-test.

Chromatin immunoprecipitation (ChIP). JEG-3 cells were incubated with 1% formaldehyde in growth medium for 10 min at room temperature, followed by adding glycin to a final concentration 125 mM for 5 min to stop the crosslinking reaction. Cells were then washed and scraped in ice-cold PBS and centrifuged, and the cell pellet was resuspended in ChIP lysis buffer (50 mM HEPES-KOH pH 7.5, 140 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 5 mM DTT, 2 mM PMSE, and 10 μg/ml leupeptin) on ice for 10 min. The cell lysate was sonicated with an ultrasonic processor (Sonics & Materials), diluted 1:3 with dilution buffer (50 mM HEPES-KOH pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 2 mM PMSE, and 10 μg/ml leupeptin), and incubated with anti-GATA2 or anti-GATA3 antibody. Rabbit or mouse IgG isotype was used as a negative control. After incubation of the immunoprecipitate with Protein G Mag Sepharose Xtra (GE Healthcare) for 4 h, the beads were washed with high salt buffer (20 mM Tris pH 8.1, 2 mM EDTA, 0.1% SDS, 1% Triton X-100, and 500 mM NaCl) and eluted with elution buffer (1% SDS in TE buffer). RNase was added, and the crosslinks were reversed by incubation at 65°C for 4 h. After proteinase K treatment at 55°C for 1 h, the DNA was purified using QIAquick Gel Extraction Kit (Qiagen). The purified DNAs were subjected to qPCR using the forward primer 5′-TCCCATAGGAGGAGAGAGCA-3′ and reverse primer 5′-CCTCATTTCCTGGGCAAGT-3′.

References

1. Miller, W. L. & Auchus, R. J. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev 32, 81–151 (2011).
2. Simard, J. et al. Molecular biology of the 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family. Endocr Rev 26, 525–582 (2005).
3. Rheaume, E. et al. Structure and expression of a new complementary DNA encoding the almost exclusive 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase in human adrenals and gonads. Mol Endocrinol 5, 1147–1157 (1991).
4. Gingras, S., Moriggl, R., Groner, B. & Simard, J. Induction of 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase type 1 gene transcription in human breast cancer cell lines and in normal mammary epithelial cells by interleukin-4 and interleukin-13. Mol Endocrinol 13, 66–81 (1999).
5. Gingras, S. & Simard, J. Induction of 3beta-hydroxysteroid dehydrogenase/isomerase type 1 expression by interleukin-4 in human normal prostate epithelial cells, immortalized keratinocytes, colon, and cervix cancer cell lines. Endocrinology 140, 4573–4584 (1999).
6. Miller, W. L. Steroid hormone biosynthesis and actions in the materno-feto-placental unit. Clin Perinatol 25, 799–817, v (1998).
7. Tremblay, Y. & Beaudoin, C. Regulation of 3 beta-hydroxysteroid dehydrogenase and 17 beta-hydroxysteroid dehydrogenase messenger ribonucleic acid levels by cyclic adenosine 3′,5′-monophosphate and phorbol myristate acetate in human chorionicarcinoma cells. Mol Endocrinol 7, 355–364 (1993).
8. Guerin, S. L., Leclerc, S., Verreault, H., Labrie, F. & Lau-Thu, V. Overlapping cis-active elements located in the first intron of the gene for type 1 3 beta-hydroxysteroid dehydrogenase modulate its transcriptional activity. Mol Endocrinol 9, 1583–1597 (1995).
9. Peng, L., Huang, Y., Jin, F., Jiang, S. W. & Payne, A. H. Transcription enhancer factor-5 and a GATA-like protein determine placental-pituitary gland.
10. Bai, H., Sakurai, T., Godkin, J. D. & Imakawa, K. Expression and potential role of GATA factors in trophoblast development. J Reprod Dev 59, 1–6 (2013).
11. Fluck, C. E. & Miller, W. L. GATA-4 and GATA-6 modulate tissue-specific transcription of the human gene for P450c17 by direct interaction with Sp1. Mol Endocrinol 18, 1144–1157 (2004).
12. Steger, D. J., Hecht, J. H. & Mellon, P. L. GATA-binding proteins regulate the human gonadotropin alpha-subunit gene in the placenta and pituitary gland. Mol Cell Biol 14, 5592–5602 (1994).
13. Abbaszade, I. et al. Isolation of a new mouse 3beta-hydroxysteroid dehydrogenase isoform, 3beta-HSD VI, expressed during early pregnancy. Endocrinology 138, 1392–1399 (1997).
14. Cheng, Y. H. & Handwerger, S. A placenta-specific enhancer of the human syncyntin gene. Biol Reprod 73, 500–509 (2005).
15. Ma, G. T. et al. GATA-2 and GATA-3 regulate trophoblast-specific gene expression in vivo. Development 124, 907–914 (1997).
16. Chang, K. H. et al. A gain-of-function mutation in DHT synthesis in DHT-resistant prostate cancer. Cell 154, 1074–1084 (2013).
17. Zhao, J. C. et al. FOXA1 acts upstream of GATA2 and AR in hormonal regulation of gene expression. Oncogene 35, 4335–4344 (2016).
18. Grass, J. A. et al. GATA-1-dependent transcriptional repression of GATA-2 via disruption of positive autoregulation and domain-wide chromatin remodeling. Proc Natl Acad Sci USA 100, 8811–8816 (2003).
19. Grass, J. A. et al. Distinct functions of dispersed GATA factor complexes at an endogenous gene locus. Mol Cell Biol 26, 7056–7067 (2006).
20. Martowicz, M. L., Grass, J. A., Boyer, M. E., Guend, H. & Bresnick, E. H. Dynamic GATA factor interplay at a multicomponent regulatory region of the GATA-2 locus. J Biol Chem 280, 1724–1732 (2005).
21. Ray, S. et al. Context-dependent function of regulatory elements and a switch in chromatin occupancy between GATA3 and GATA2 regulate Gata2 transcription during trophoblast differentiation. J Biol Chem 284, 4978–4988 (2009).
22. Piao, Y. S., Peloketo, H., Vilko, P. & Vilko, R. The proximal promoter region of the gene encoding human 17beta-hydroxysteroid dehydrogenase type 1 contains GATA, AP-2, and Sp1 response elements: analysis of promoter function in chorionicarcinoma cells. Endocrinology 138, 3417–3425 (1997).
23. Shen, N., Yvig-Ohana, N. & Orly, J. Transcriptional regulation of the cholesterol side chain cleavage cytochrome P450 gene (CYP11A1) revisited: binding of GATA, cyclic adenosine 3′,5′-monophosphate response element-binding protein and activating protein (AP)-1 proteins to a distal novel cluster of cis-regulatory elements potentiates AP-2 and steroidogenic factor-1-dependent gene expression in the rodent placenta and ovary. Mol Endocrinol 21, 948–962 (2007).
24. Yang, F. M., Feng, S. J., Lai, T. C. & Hu, M. C. A calreticulin-dependent nuclear export signal is involved in the regulation of liver receptor homologue-1 protein folding. Biochem J 471, 199–209 (2015).

Acknowledgements

We thank Dr. Wei-Yi Che for advice on ChIP-qPCR methodology and GATA2 ChIP-seq data analysis. This work was supported by grants from the Ministry of Science and Technology, Taiwan (MOST 104-2320-B-002-028).
Author Contributions
T.C.L. performed experiments and prepared the manuscript. Y.S.L. built initial constructs. H.F.L., Y.S.L. and P.Y.H. performed experiments. M.K.S. provided materials and gave technical support. M.C.H. designed the study, interpreted data and wrote the manuscript.

Additional Information
Supplementary information accompanies this paper at doi:10.1038/s41598-017-04133-6

Competing Interests: The authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017